Regeneron Pharmaceuticals (REGN) said Monday it has won the bankruptcy auction to acquire substantially all assets of 23andMe for $256 million.
The acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services business units, its Biobank, and related assets. The transaction does not include 23andMe's Lemonaid Health business.
The deal is expected to close in Q3, pending closing conditions including bankruptcy court and regulatory approvals.
Following the acquisition, 23andMe will operate as a wholly owned subsidiary of Regeneron and continue its personal genomics services.
Regeneron said it will maintain compliance with 23andMe's consumer privacy policies and applicable laws with respect to the treatment of customer data.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。